Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S3W-29331 · Session 3

Which NHS boards make sentinel node biopsy available to patients with breast cancer.

Answered Asked by Dr Richard Simpson Lab Lodged 24 Nov 2009

The question

To ask the Scottish Executive which NHS boards make sentinel node biopsy available to patients with breast cancer.

The answer

Answered by Nicola Sturgeon on 3 Dec 2009 · 9 days after it was lodged, on time

Sentinel node biopsy is currently available to all breast cancer patients in Scotland where this is clinically appropriate. Services are configured so that all suitable patients are offered the procedure at their nearest breast cancer unit providing it.
All breast surgeons are required to undertake the necessary training before performing this procedure and have to comply with nationally agreed protocols regarding training and monitoring. Training in the sentinel node biopsy technique is delivered locally and consideration is currently being given to the training needs of new recruits.
I refer the member to the answer to question S3W-18880 on 8 January 2009 where I outlined that Better Cancer Care: An Action Plan stated that the Scottish Government together with the Regional Cancer Advisory Groups and NHS boards would explore the feasibility of sentinel node biopsy being made available across NHSScotland. Scottish Government has not committed to undertaking a feasibility study into the availability of sentinel node biopsy.
The regional cancer networks have been working with their constituent NHS boards to progress making sentinel node biopsy available across NHSScotland and as the above information denotes, the procedure is now available across all regions.
All answers to written parliamentary questions are available on the Parliament''s website, the search facility for which can be found at:
http://www.scottish.parliament.uk/Apps2/Business/PQA/Default.aspx.

In the Official Report

No contribution in the Official Report cites S3W-29331 by reference.